CT引导经臀前列腺穿刺活检用于无直肠通路患者前列腺系统取样的13年单中心经验
回顾性分析13年间65例无直肠通路患者共73次CT引导经臀前列腺穿刺活检,技术成功率97.3%(71/73),恶性肿瘤检出率43.6%(31/71),平均Gleason评分7分;仅1例(1.4%)出现无症状前列腺周围血肿,平均有效辐射剂量18.5 mSv,作者认为该技术安全可靠。
要点
- 无直肠通路患者前列腺取样困难,CT引导经臀穿刺技术成功率97.3%。
- 恶性检出率43.6%,平均Gleason评分7分,可用于诊断高级别前列腺癌。
- 仅1例无症状前列腺周围血肿(1.4%),平均有效辐射剂量18.5 mSv。
核心结论
- CT引导经臀前列腺穿刺活检对无直肠通路男性前列腺癌检测高度安全可靠,可能对诊断高级别前列腺癌尤其有效,对局灶性病变患者单侧活检可能有效,该技术辐射暴露可接受。
研究设计与样本
- 单中心13年(2002-2015年)回顾性研究,65例患者共73次活检,复习电子病历获取操作细节与并发症,恶性与良性队列的平均PSA和穿刺针数用Student t检验比较。
关键影像表现/征象
- 技术成功率97.3%(71/73),平均穿刺针数8针(范围3-28)。
- 71次成功活检中43.6%(31/71)为恶性,平均Gleason评分7分(范围6-10);56.3%(40/71)为良性组织。
- 14例接受手术的患者中Gleason评分一致71.4%(10/14),不一致28.6%(4/14;活检Gleason 6而手术标本Gleason 7)。
- 唯一并发症为无症状前列腺周围血肿(1/73;1.4%)。
- 平均有效辐射剂量18.5 mSv(中位数15.0,范围4.4-86.2)。
诊断标准与关键数值
- 恶性与良性队列平均PSA差异无统计学意义(p=0.06),穿刺针数差异无统计学意义(p=0.33)。
临床应用与阅片要点
- 对无直肠通路患者,CT引导经臀途径可实现前列腺系统取样,技术成功率97.3%。
- 作者认为该技术安全可靠,可用于此类患者前列腺癌检测。
- 作者认为该技术可能对诊断高级别前列腺癌尤其有效,对局灶性病变患者单侧活检可能有效。
- 作者认为该技术辐射暴露可接受。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of our study was to examine the safety and diagnostic utility of transgluteal CT-guided prostate biopsy for prostate sampling in patients without rectal access.
METHODS: Seventy-three biopsies were performed in 65 patients over a 13-year period (2002-2015). Mean prostate-specific antigen (PSA) at biopsy was 7.8 ng/mL (range 0.37-31.5). Electronic medical records were reviewed for procedural details and complications. Mean PSA and number of cores in malignant and benign cohorts were compared with Student's t test.
RESULTS: Technical success rate was 97.3% (71/73; mean cores 8, range 3-28). Of these, 43.6% (31/71) yielded malignancy (mean Gleason score 7, range 6-10) and 56.3% (40/71) yielded benign tissue. The only complication was an asymptomatic periprostatic hematoma (1/73; 1.4%). In 14 patients who underwent surgery, Gleason scores were concordant in 71.4% (10/14) and discordant in 28.6% (4/14; Gleason 6 on biopsy but Gleason 7 on surgical specimen). Mean effective radiation dose was 18.5 mSv (median 15.0, range 4.4-86.2). There was no significant difference in either mean PSA (p = 0.06) or number of core specimens (p = 0.33) between malignant and benign cohorts.
CONCLUSION: CT-guided transgluteal prostate biopsy is highly safe and reliable for the detection of prostate cancer in men without rectal access.
KEY POINTS: • Prostate cancer detection in men without rectal access is challenging. • CT-guided transgluteal prostate biopsy is safe and effective in these patients. • CT-guided biopsy may be particularly effective in diagnosing high-grade prostate cancer. • Unilateral CT-guided biopsy may be effective in patients with focal lesions. • The radiation exposure with this technique is acceptable.
引用
- Olson MC, Atwell TD, Mynderse LA, et al. CT-guided transgluteal biopsy for systematic sampling of the prostate in patients without rectal access: a 13-year single-center experience. Eur Radiol. 2016. PMID: 27975149. doi:10.1007/s00330-016-4694-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。